Strategic Partnerships Hardy Diagnostics has a history of strategic collaborations with innovative tech and diagnostic players (NEMIS Technologies, Gradientech, Applied BioCode) to expand capabilities and product reach, signaling opportunistic channels for co-marketing, distributorships, and integrated solutions.

Rapid Test Portfolio The upcoming launch of rapid lateral flow assays and recent enrichement media for detecting resistant organisms indicates a growing portfolio in rapid diagnostics, creating cross-sell opportunities to existing microbiology labs and hospital networks seeking faster results.

Global Lab Footprint With international partnerships and a global user base for microbiology products, there is potential to expand into new regional markets and secure multi-year supply agreements with distributors and reference labs seeking validated, ISO 13485 certified solutions.

Gov and Public Sector GSA MAS award history and FDA-licensed manufacturing position Hardy Diagnostics well for government procurement programs, suggesting opportunities in federal and state lab contracts, as well as public health initiatives requiring validated culture media and rapid diagnostics.

Growth and Capability As an employee-owned, fast-growing company with a strong quality and sustainability profile, Hardy Diagnostics can leverage its branding to target mid-to-large microbiology labs and hospital systems aiming for stable supplier relationships, green/fit-friendly suppliers, and long-term purchasing partnerships.